Featured MNV Articles:
More articles: 1 2 3 4 5 6 7 next »
|Notable Tuesday Option Activity: VMW, GPC, MDR
Tuesday, April 18, 3:40 PM ET, by Market News Video Staff
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...
DK Crosses Critical Technical Indicator
Wednesday, April 19, 3:50 PM ET, by Market News Video Staff
In trading on Wednesday, shares of Delek US Holdings Inc (DK) entered into oversold territory, ...
Short Interest Falls 72.7% For MDR
Wednesday, April 26, 1:10 PM ET, by Market News Video Staff
The most recent short interest data has been released for the 04/13/2017 settlement date, which ...
Notable Two Hundred Day Moving Average Cross - MDR
Thursday, May 4, 11:06 AM ET, by Market News Video Staff
In trading on Thursday, shares of McDermott International Inc (MDR) crossed below their 200 day ...
Notable Friday Option Activity: PENN, DIN, MDR
Friday, May 5, 3:23 PM ET, by Market News Video Staff
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...
The Math Shows RALS Can Go To $41
By Dividend Channel Staff, Friday, August 18, 9:52 AM ET
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares RAFI Long/Short ETF (AMEX:RALS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $41.38 per unit.
With RALS trading at a recent price near $37.61 per unit, that means that analysts see 10.03% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RALS's underlying holdings with notable upside to their analyst target prices are Delek US Holdings Inc (NYSE:DK), PDL BioPharma Inc (NASDAQ:PDLI), and McDermott International Inc (NYSE:MDR). Although DK has traded at a recent price of $20.88/share, the average analyst target is 30.37% higher at $27.22/share. Similarly, PDLI has 28.21% upside from the recent share price of $2.73 if the average analyst target price of $3.50/share is reached, and analysts on average are expecting MDR to reach a target price of $7.12/share, which is 25.22% above the recent price of $5.69. Below is a twelve month price history chart comparing the stock performance of DK, PDLI, and MDR:
Below is a summary table of the current analyst target prices discussed above:
|Name ||Symbol ||Recent Price ||Avg. Analyst 12-Mo. Target ||% Upside to Target|
|ProShares RAFI Long/Short ETF ||RALS ||$37.61 ||$41.38 ||10.03%|
|Delek US Holdings Inc ||DK ||$20.88 ||$27.22 ||30.37%|
|PDL BioPharma Inc ||PDLI ||$2.73 ||$3.50 ||28.21%|
|McDermott International Inc ||MDR ||$5.69 ||$7.12 ||25.22%|
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on DK — FREE
Get the latest Zacks research report on PDLI — FREE
Get the latest Zacks research report on MDR — FREE
This Article's Word Cloud: